Azerbaijan vs IDA blend: Access to anti-retroviral drugs, female
Azerbaijan
98.0%
in 2024
IDA blend
88.4%
in 2024
Azerbaijan rank
1st
IDA blend rank
3rd
Access to anti-retroviral drugs, female over time
- Azerbaijan
- IDA blend
How they compare
Azerbaijan currently reports 98.0% against 88.4% in IDA blend, a difference of 9.6%.
That makes Azerbaijan's figure about 1.1 times IDA blend's.
The two have swapped places 1 time across 24 shared years of data; in 2000 it was IDA blend ahead.
Azerbaijan ranks 1st and IDA blend ranks 3rd of 141 countries.
Across the 3 decades both report, Azerbaijan averaged higher in 1 and IDA blend in 2.
Head to head by decade
| Decade | Azerbaijan | IDA blend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.0% | 5.4% | 4.4% | IDA blend |
| 2010s | 32.0% | 51.6% | 19.6% | IDA blend |
| 2020s | 83.6% | 83.0% | 0.6% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Azerbaijan or IDA blend?
- Azerbaijan, at 98.0% against 88.4% in IDA blend as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Azerbaijan and IDA blend?
- 9.6%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and IDA blend?
- 24 years are reported by both, from 2000 to 2024.
- How do Azerbaijan and IDA blend rank globally for access to anti-retroviral drugs, female?
- Azerbaijan ranks 1st and IDA blend ranks 3rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.